Samsung Biologics Secures Nearly 98% Stake in PolyPeptide
Samsung Biologics announced on Nov. 2 that it recorded a final subscribed stake of 97.98% in the tender offer for the global peptide contract development and manufacturing organization (CDMO) company ‘PolyPeptide Group’, satisfying not only the minimum acceptance condition for the transaction but al
On November 2, Samsung Biologics announced it had acquired nearly 98% of PolyPeptide Group, securing the minimum acceptance condition for the transaction and meeting the requirement for the compulsory purchase of remaining minority shares. The final results of the tender offer, conducted from October 12 to October 30, showed 97.98% of shares subscribed, translating to 97.66% of the target.
This surpassed both the 66.7% minimum condition and the 90% compulsory purchase threshold. Independent verification will be announced on November 5. Samsung Biologics plans to complete the compulsory purchase after obtaining regulatory approvals in Europe, India, Australia, and Brazil, aiming for a full acquisition by year-end or early next year.
The deal, valued at 1.46 billion Swiss francs ($2.08 billion), marks Samsung Biologics' largest M&A in the domestic pharmaceutical and bio industry, expanding its peptide service business, which is crucial for diabetes and obesity treatments. The global obesity treatment market is projected to reach $150 billion by 2035, driving demand for peptide-based therapies.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
